Licochalcone B alleviates atherosclerosis by inhibiting endothelial inflammation via targeting the KEAP1/NRF2/NF-κB signalling pathway.
Fuente:
PubMed
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo científico |
| Lenguaje: | en |
| Publicado: |
Phytomedicine : international journal of phytotherapy and phytopharmacology
2026
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1868266041763692545 |
|---|---|
| author | Liao, Zhao-Fu Zhou, Wan-Qing Du, Shuang-Qiu Liu, Xiao-Meng Yao, Jia Din, Zaheer Ud Shi, Zhen-Can Cai, Meng-Yun Wang, Song-Hua Tang, Xin-Bin Ding, Zi-Yun Li, Xiao-Ru Wu, Zhu-Guo Xu, Shun Qi, Yi Luo, Hui Xiong, Xing-Dong |
| author_facet | Liao, Zhao-Fu Zhou, Wan-Qing Du, Shuang-Qiu Liu, Xiao-Meng Yao, Jia Din, Zaheer Ud Shi, Zhen-Can Cai, Meng-Yun Wang, Song-Hua Tang, Xin-Bin Ding, Zi-Yun Li, Xiao-Ru Wu, Zhu-Guo Xu, Shun Qi, Yi Luo, Hui Xiong, Xing-Dong Liao, Zhao-Fu Zhou, Wan-Qing Du, Shuang-Qiu Liu, Xiao-Meng Yao, Jia Din, Zaheer Ud Shi, Zhen-Can Cai, Meng-Yun Wang, Song-Hua Tang, Xin-Bin Ding, Zi-Yun Li, Xiao-Ru Wu, Zhu-Guo Xu, Shun Qi, Yi Luo, Hui Xiong, Xing-Dong |
| collection | PubMed - marine biology |
| contents | Licochalcone B alleviates atherosclerosis by inhibiting endothelial inflammation via targeting the KEAP1/NRF2/NF-κB signalling pathway. Liao, Zhao-Fu Zhou, Wan-Qing Du, Shuang-Qiu Liu, Xiao-Meng Yao, Jia Din, Zaheer Ud Shi, Zhen-Can Cai, Meng-Yun Wang, Song-Hua Tang, Xin-Bin Ding, Zi-Yun Li, Xiao-Ru Wu, Zhu-Guo Xu, Shun Qi, Yi Luo, Hui Xiong, Xing-Dong Animals Kelch-Like ECH-Associated Protein 1 Chalcones Atherosclerosis NF-E2-Related Factor 2 NF-kappa B Signal Transduction Mice Anti-Inflammatory Agents Inflammation Male Humans Mice, Inbred C57BL Diet, High-Fat Apolipoproteins E Mice, Knockout, ApoE Glycyrrhiza Atherosclerosis is a chronic inflammatory disorder of the arterial subendothelium that remains a major clinical challenge. Licochalcone B (LCB), a licorice-derived flavonoid, has been documented to display anti-inflammatory effects; however, its therapeutic potential for atherosclerosis remains unknown. To evaluate the efficacy of LCB against atherosclerosis and to uncover the mechanisms involved. To establish an atherosclerosis model, ApoE mice were fed a high-fat diet, after which they received treatment with either LCB at two different doses or simvastatin for 8 weeks. Therapeutic efficacy was evaluated via histological analysis. In vitro studies employing transcriptome sequencing, Western blotting, immunofluorescence, cellular thermal shift assay, surface plasmon resonance, molecular docking, and RNA interference were conducted to examine the anti-inflammatory mechanisms of LCB in endothelial cells. LCB treatment significantly attenuated atherosclerotic progression, as evidenced by reduced plaque area and increased plaque stability, along with suppression of endothelial inflammation in ApoE mice. Mechanistically, LCB directly targeted KEAP1 in endothelial cells, promoting its autophagic degradation. This event initiated an NRF2-dependent antioxidant response, subsequently suppressed NF-κB p65 phosphorylation at Ser276, and ultimately downregulated VCAM1 and ICAM1 in inflamed endothelial cells. This study offers the first demonstration that LCB attenuates atherosclerosis through the suppression of endothelial inflammation by targeting the KEAP1/NRF2/NF-κB axis. Notably, LCB exhibited no hepatotoxicity or nephrotoxicity, underscoring its suitability as a safe pharmacological agent for atherosclerotic cardiovascular disease. |
| format | Artículo científico |
| id | pubmed_42208107 |
| institution | PubMed |
| language | en |
| publishDate | 2026 |
| publisher | Phytomedicine : international journal of phytotherapy and phytopharmacology |
| record_format | pubmed |
| spellingShingle | Licochalcone B alleviates atherosclerosis by inhibiting endothelial inflammation via targeting the KEAP1/NRF2/NF-κB signalling pathway. Liao, Zhao-Fu Zhou, Wan-Qing Du, Shuang-Qiu Liu, Xiao-Meng Yao, Jia Din, Zaheer Ud Shi, Zhen-Can Cai, Meng-Yun Wang, Song-Hua Tang, Xin-Bin Ding, Zi-Yun Li, Xiao-Ru Wu, Zhu-Guo Xu, Shun Qi, Yi Luo, Hui Xiong, Xing-Dong Animals Kelch-Like ECH-Associated Protein 1 Chalcones Atherosclerosis NF-E2-Related Factor 2 NF-kappa B Signal Transduction Mice Anti-Inflammatory Agents Inflammation Male Humans Mice, Inbred C57BL Diet, High-Fat Apolipoproteins E Mice, Knockout, ApoE Glycyrrhiza Licochalcone B alleviates atherosclerosis by inhibiting endothelial inflammation via targeting the KEAP1/NRF2/NF-κB signalling pathway. Liao, Zhao-Fu Zhou, Wan-Qing Du, Shuang-Qiu Liu, Xiao-Meng Yao, Jia Din, Zaheer Ud Shi, Zhen-Can Cai, Meng-Yun Wang, Song-Hua Tang, Xin-Bin Ding, Zi-Yun Li, Xiao-Ru Wu, Zhu-Guo Xu, Shun Qi, Yi Luo, Hui Xiong, Xing-Dong Animals Kelch-Like ECH-Associated Protein 1 Chalcones Atherosclerosis NF-E2-Related Factor 2 NF-kappa B Signal Transduction Mice Anti-Inflammatory Agents Inflammation Male Humans Mice, Inbred C57BL Diet, High-Fat Apolipoproteins E Mice, Knockout, ApoE Glycyrrhiza Atherosclerosis is a chronic inflammatory disorder of the arterial subendothelium that remains a major clinical challenge. Licochalcone B (LCB), a licorice-derived flavonoid, has been documented to display anti-inflammatory effects; however, its therapeutic potential for atherosclerosis remains unknown. To evaluate the efficacy of LCB against atherosclerosis and to uncover the mechanisms involved. To establish an atherosclerosis model, ApoE mice were fed a high-fat diet, after which they received treatment with either LCB at two different doses or simvastatin for 8 weeks. Therapeutic efficacy was evaluated via histological analysis. In vitro studies employing transcriptome sequencing, Western blotting, immunofluorescence, cellular thermal shift assay, surface plasmon resonance, molecular docking, and RNA interference were conducted to examine the anti-inflammatory mechanisms of LCB in endothelial cells. LCB treatment significantly attenuated atherosclerotic progression, as evidenced by reduced plaque area and increased plaque stability, along with suppression of endothelial inflammation in ApoE mice. Mechanistically, LCB directly targeted KEAP1 in endothelial cells, promoting its autophagic degradation. This event initiated an NRF2-dependent antioxidant response, subsequently suppressed NF-κB p65 phosphorylation at Ser276, and ultimately downregulated VCAM1 and ICAM1 in inflamed endothelial cells. This study offers the first demonstration that LCB attenuates atherosclerosis through the suppression of endothelial inflammation by targeting the KEAP1/NRF2/NF-κB axis. Notably, LCB exhibited no hepatotoxicity or nephrotoxicity, underscoring its suitability as a safe pharmacological agent for atherosclerotic cardiovascular disease. |
| title | Licochalcone B alleviates atherosclerosis by inhibiting endothelial inflammation via targeting the KEAP1/NRF2/NF-κB signalling pathway. |
| topic | Animals Kelch-Like ECH-Associated Protein 1 Chalcones Atherosclerosis NF-E2-Related Factor 2 NF-kappa B Signal Transduction Mice Anti-Inflammatory Agents Inflammation Male Humans Mice, Inbred C57BL Diet, High-Fat Apolipoproteins E Mice, Knockout, ApoE Glycyrrhiza |
| url | https://pubmed.ncbi.nlm.nih.gov/42208107/ |